consist
rehydr
stabil
blood
pressur
control
fever
pain
ebov
subdivid
speci
zair
ebovz
sudan
ebov
reston
ebovr
tai
forest
ebovtf
also
known
divoir
ebola
viru
bundibugyo
ebovb
ebovz
ebov
predomin
ebov
associ
known
outbreak
pathogen
ebovr
caus
fatal
infect
nonhuman
primat
ebovtf
caus
singl
nonfat
human
infect
ebovz
ebov
ebovb
often
caus
sever
hemorrhag
diseas
markedli
high
case
fatal
rate
tabl
ebov
classifi
biosafeti
level
agent
categori
potenti
bioterror
agent
center
diseas
control
cdc
prevent
first
describ
filovirida
ebola
marburg
togeth
paramyxovirida
rhabdovirida
bornavirida
belong
order
mononegaviral
ebola
viru
uniform
diamet
nm
form
filament
nm
long
fig
classic
virion
contain
singl
genom
copi
polyploid
virion
also
describ
contain
two
copi
genom
viral
rna
genom
encod
seven
protein
np
nucleoprotein
polymeras
cofactor
matrix
protein
gp
glycoprotein
transcript
activ
secondari
matrix
protein
l
larg
rnadepend
rna
polymeras
wherea
np
gp
may
involv
viral
entri
l
polymeras
may
attract
target
viral
rna
synthesi
inhibitor
therapeut
strategi
ebov
infect
classifi
differ
categori
accord
target
action
recombin
nematod
anticoagul
protein
recombin
human
activ
protein
c
rhapc
aim
treat
clinic
symptom
coagulopathi
sepsi
respect
observ
infect
patient
specif
ebov
infect
ii
small
interf
rna
sirna
posit
charg
phosphorodiamid
morpholino
oligom
pmo
plu
iii
monoclon
antibodi
mab
suppress
viremia
viru
spread
pmo
plu
antisens
therapi
shown
protect
rhesu
monkey
ebovz
cynomolgu
monkey
marburg
viru
infect
safeti
pharmacokinet
profil
pmo
plu
document
pmo
compos
compos
target
gene
ebov
target
np
gene
marburg
viru
progress
late
stage
clinic
develop
meanwhil
potenti
sirna
postexposur
treatment
strategi
peopl
infect
ebv
convincingli
demonstr
postexposur
antibodi
prophylaxi
shown
protect
nonhuman
primat
nhp
filoviru
either
marburg
ebola
viru
infect
even
delay
hour
revers
advanc
ebov
infect
nonhuman
primat
zmapp
protect
rhesu
macaqu
impact
ethic
consider
trespass
demand
materi
time
deploy
ebola
vaccin
come
viabl
ebola
vaccin
candid
rvsv
recombin
vesicular
stomat
viru
ebovzgp
glycoprotein
rrabv
recombin
rabi
viru
ebovzgp
recombin
adenoviru
serotyp
ebovzgp
vlp
viruslik
particl
ebovzgp
recombin
human
parainfluenza
viru
type
ebovzgp
rcmv
recombin
cytomegaloviru
ebovznp
nucleoprotein
rebov
recombin
ebola
viru
subunit
vaccin
tlr
tolllik
receptor
agonist
would
feasibl
develop
prevent
vaccin
ebola
viru
infect
primat
ie
cynomolgu
macaqu
alreadi
demonstr
nabel
cowork
vlp
subsequ
shown
protect
nonhuman
primat
lethal
ebola
viru
challeng
vsvbase
vaccin
express
ebovz
glycoprotein
complet
protect
cynomolgu
macaqu
aerosol
challeng
ebovz
complet
protect
cynomolgu
macaqu
bundibugyo
ebola
viru
challeng
also
achiev
vsvbase
vaccin
singl
intramuscular
vaccin
venezuelan
equin
enceph
viru
veev
replicon
particl
vrp
express
ebovsgp
combin
vrp
express
ebov
gp
provid
complet
protect
intramuscular
challeng
either
ebov
ebovz
cynomolgu
macaqu
antibodi
play
critic
role
rvsvebovzgpmedi
protect
lethal
ebovz
challeng
cynomolgu
macaqu
highli
immunogen
fragment
mfl
aa
deriv
ebovzgp
elicit
high
level
neutral
antibodi
mice
vlp
vaccin
would
hold
great
potenti
fight
wild
ape
extinct
could
use
vaccin
captiv
chimpanze
protect
wild
chimpanze
sever
phase
vaccin
clinic
trial
progress
start
expect
get
vaccin
commerci
avail
end
although
interferon
discov
end
medic
use
limit
essenti
sever
side
effect
principl
similar
experienc
acut
influenza
viru
infect
yet
interferon
last
decad
part
togeth
ribavirin
standard
care
soc
treatment
hepat
c
whenev
new
viru
emerg
reemerg
howev
potenti
use
interferon
case
outbreak
sar
coronaviru
epidem
interferon
envisag
therapi
ebov
infect
practic
viewpoint
potenti
use
pegyl
interferon
treatment
ebov
infect
facilit
increas
avail
use
treatment
hepat
c
overtaken
directact
antivir
daa
addit
interferon
could
induc
number
ifitm
interferoninduc
transmembran
protein
exert
antivir
activ
broad
rang
virus
includ
hcv
sar
coronaviru
also
vsv
ebov
marburg
west
nile
viru
possibl
virus
could
consider
extend
scope
interferonbas
therapi
surpris
observ
made
bray
et
al
sadenosyllhomocystein
sah
hydrolas
inhibitor
could
induc
massiv
increas
interferona
product
ebovinfect
mice
whether
massiv
interferon
product
epiphenomen
causal
relat
protect
effect
ebola
never
resolv
reason
induct
fig
structur
ebola
viru
ebolaviru
particl
characterist
filament
shape
shown
negativestrand
rna
genom
found
center
particl
encapsid
form
nucleocapsid
togeth
polymeras
complex
embed
viru
membran
trimer
glycoprotein
spike
beneath
membran
matrix
protein
facilit
morphogenesi
bud
viru
particl
reprint
permiss
new
england
journal
medicin
massiv
interferon
induct
possibl
hypothesi
sah
hydrolas
inhibitor
block
methyl
rna
transcrib
rna
filoviru
genom
thu
prevent
releas
mrna
rna
duplex
gener
increas
level
doublestrand
ds
rna
molecul
act
power
induc
interferon
sah
hydrolas
inhibitor
may
specif
block
cap
ribos
omethyl
viral
mrna
may
provid
molecular
signatur
distinct
self
nonself
mrna
depend
rna
sensor
addit
natur
neplanocin
b
c
f
enantiom
isom
neplanocin
synthes
fig
potenti
vivo
therapi
ebov
infect
remain
assess
fig
describ
inhibitor
rnadepend
rna
polymeras
hail
possibl
leap
ahead
filoviru
therapeut
propos
function
nonoblig
rna
chain
termin
role
possibl
sah
hydrolas
inhibitor
even
consid
even
importantli
potenti
activ
rhabdoviru
vsv
even
touch
upon
although
much
learn
filoviru
therapeut
action
rhabdovirus
vsv
especi
regard
mode
action
rna
polymeras
level
consid
adenosin
analog
structur
modif
cnucleosid
instead
usual
nglycosid
ii
replac
group
origin
compound
synthes
seri
fig
hypoxanthin
deriv
report
purin
nucleosid
phosphorylas
transitionst
inhibitor
antivir
activ
report
hypoxanthin
deriv
probabl
antivir
effect
ampli
discuss
previous
potenti
favipiravir
broadspectrum
activ
share
ribavirin
wide
varieti
rna
virus
ie
influenza
approv
japan
treatment
influenza
viru
infect
arena
bunya
rna
virus
ie
flavi
picorna
noro
henc
surpris
also
activ
filovirida
casu
ebov
structur
favipiravir
close
relat
ribavirin
fig
share
carboxamid
c
nh
moieti
perhap
favipiravir
could
consid
specif
antivir
version
ribavirin
target
viral
rna
polymeras
although
ribavirin
princip
target
imp
dehydrogenas
convert
activ
metabolit
act
viral
rna
polymeras
favipiravir
first
convert
phosphoribosyl
deriv
subsequ
triphosph
fig
could
interact
rna
polymeras
inhibitor
princip
direct
competit
gtp
mention
vsv
would
serv
adequ
surrog
viru
judg
potenti
favipiravir
treatment
ebov
infect
vivo
anim
model
vsv
infect
newborn
mice
describ
mani
year
ago
griffithsin
redalga
deriv
lectin
bind
termin
mannos
residu
asparagin
n
link
man
structur
found
envelop
hcv
sar
coronaviru
ebov
griffithsin
similar
lectin
may
potenti
use
treatment
ebov
infect
numer
lectin
start
concanavalin
cyanovirin
n
mannosespecif
plant
lectin
describ
potenti
antivir
agent
proven
particularli
activ
host
cellular
er
aglucosidas
ii
essenti
matur
viral
glycosyl
envelop
protein
inhibit
glycan
process
enzym
lead
misfold
degrad
viral
glycoprotein
imino
sugar
deriv
glucos
mimic
nitrogen
atom
replac
oxygen
competit
inhibit
er
aglucosidas
ii
one
deriv
efficaci
lethal
dengu
viru
infect
mous
model
three
deriv
name
fig
suppress
mortal
marburg
ebola
viru
infect
mice
fgi
gaithersburg
md
three
compound
report
exhibit
vivo
efficaci
ebov
first
one
also
exhibit
activ
marburg
viru
third
one
activ
rift
valley
viru
dengu
fever
viru
well
ebov
structur
reveal
fig
structur
mode
action
specul
upon
fascin
perfectli
symmetr
structur
tell
us
someth
mode
antivir
action
nevertheless
remain
enigmat
far
found
exhibit
antifiloviru
activ
vitro
vivo
mice
infect
ebov
marburg
viru
fig
found
act
scaveng
reactiv
oxygen
speci
vitro
also
inhibitori
rift
valley
fever
viru
lassa
viru
venezuelan
equin
enceph
viru
ebola
viru
entri
host
cell
requir
cholesterol
transport
niemannpick
viral
entri
block
benzylpiperazin
adamantan
diamid
fig
variou
hit
compound
among
benzodiazepin
compound
also
identifi
entri
inhibitor
filovirus
fig
two
structur
unrel
compound
fig
name
rhodamin
deriv
rigid
amphipath
fusion
inhibitor
rafi
prevent
fusion
viral
cellular
membran
specif
activ
envelop
virus
inhibit
entri
filovirus
includ
ebov
envelop
virus
influenza
hiv
pox
arena
bunya
paramyxoand
flavivirus
directli
demonstr
surmis
would
inhibit
replic
filovirus
ebov
rel
simpl
structur
also
shown
effect
prevent
virusinduc
mortal
ebov
consid
prime
candid
curtail
ongo
ebov
epidem
serm
previous
approv
fda
total
chanc
found
inhibit
ebov
infect
fig
compound
concern
clomiphen
toremifen
would
activ
ebov
offtarget
effect
compound
interfer
late
step
viral
entri
like
affect
trigger
fusion
serm
immedi
action
class
fdaapprov
drug
readili
repurposid
treatment
filoviru
infect
ion
channel
blocker
amiodaron
dronedaron
verapamil
found
inhibit
cell
entri
filovirus
ie
ebov
particular
amiodaron
multiion
channel
inhibitor
use
clinic
antiarrhythm
agent
inhibit
benzodiaz
epin
deriva
com
pound
fig
viral
entri
inhibitor
benzylpiperazin
adamantin
diamid
benzodiazepin
deriv
compound
filoviru
entri
within
rang
achiev
serum
antiarrhythm
therapi
human
ie
mgml
amiodaron
also
inhibit
new
world
arenaviru
guanarito
old
world
arenaviru
lassa
rhabdovirida
vesicular
stomat
viru
bunyavirida
hantaan
inhibit
fig
ebov
rna
transcript
inhibitor
fig
found
inhibit
replic
nonseg
negativestrand
rna
virus
ebov
vsv
vesicular
stomat
viru
earlier
studi
connor
et
al
smith
et
al
note
inhibit
vsv
ie
inhibit
heatshock
protein
presag
inhibit
ebov
replic
endoplasm
reticulum
er
chaperon
heat
shock
kda
protein
identifi
ebovassoci
host
factor
envelop
virus
vsv
small
molecul
epigallocatechin
gallat
fig
bind
atpbind
site
therebi
disturb
chaperon
function
requir
ebov
infect
besid
epigallocatechin
gallat
vari
molecul
identifi
inhibitor
whether
also
inhibitori
vsv
ebov
infect
remain
determin
enzym
catalyz
first
ratelimit
step
degrad
heme
carbon
monoxid
co
free
iron
fe
subsequ
oxid
fe
store
ferritin
biliverdin
subsequ
reduc
bilirubin
upregul
substrat
heme
also
variou
nonhem
induc
heat
shock
inflammatori
cytokin
endotoxin
oxid
stress
would
also
suppress
ebov
replic
level
viral
entri
bud
level
ebov
transcriptionrepl
would
also
seem
mandatori
examin
whether
also
suppress
vsv
replic
certainli
repres
novel
therapeut
strategi
ebov
infect
number
small
molecul
prevent
cathepsin
l
cleavag
viral
glycoprotein
identifi
inhibit
entri
sar
coronaviru
hendra
nipah
andor
ebov
fig
compound
need
optim
develop
antivir
drug
use
treatment
target
virus
chloroquin
known
sinc
specif
synthes
antimalari
agent
gradual
dismiss
antimalari
therapi
prophylaxi
due
continu
emerg
chloroquineresist
plasmodium
falciparum
strain
pleiad
antivir
effect
vari
endocytosi
exocytosi
viral
particl
addit
downregul
ifng
tnfa
product
tnfa
receptor
shown
activ
inhibit
sar
coronaviru
inhibit
human
coronaviru
infect
newborn
mice
surprisingli
also
found
protect
mice
ebov
infect
vivo
fig
ebola
viru
ebov
first
identifi
hemorrhag
fever
viru
year
aid
recogn
year
hiv
discov
etiolog
agent
ebov
regularli
led
emerg
epidem
particularli
congo
zair
sudan
uganda
recent
stir
worldwid
concern
breakthrough
west
africa
start
decemb
spread
three
countri
guinea
sierra
leon
liberia
mortal
rate
reach
global
death
toll
still
rise
still
vaccin
treatment
avail
although
ebov
highli
contagi
sensit
vari
welldefin
compound
major
compound
tabl
target
either
viral
entri
viru
replicationtranscript
work
ebov
bsl
biosafeti
level
highest
level
requir
make
ebov
handl
laboratori
world
point
howev
mechan
replic
ebov
belong
filovirida
follow
strategi
similar
vesicular
stomat
viru
vsv
belong
rhabdovirida
sens
vsv
could
consid
surrog
viru
ebov
mean
sever
compound
previous
describ
inhibitor
vsv
revisit
therapeut
agent
ebov
vice
versa
potenti
antiebov
therapi
could
preevalu
antivsv
activ
pertin
compound
neplanocin
deriv
target
sadenosyllhomocystein
sah
hydrolas
favipiravir
target
viral
rna
polymeras
